Abstract
Objective
To examine the perceived importance and frequency with which out-of-pocket medication costs are discussed between rheumatologists and patients with rheumatoid arthritis (RA) in Canada.
Methods
A cross-sectional online survey was distributed to patients with RA and rheumatologists; both were asked to rate their perceived importance of discussing medication costs, and how often these discussions occurred. Predictors of (1) patients discussing costs with their rheumatologist and (2) the perceived importance of discussing medication cost for patients were explored.
Results
Seventy-eight patients and 64 rheumatologists completed the survey; 68% patients and 75% of physicians rated the perceived importance of discussing medication costs as “quite” or “very important”; 22% of patients reported never talking about medication cost, but no physicians reported never discussing costs with patients. The only predictor of talking about cost among patients (at 10% level) was whether they perceived it as highly important (p = 0.058). Higher perceived importance of discussing out-of-pocket costs was associated with a more positive attitude to shared decision-making (p = 0.044).
Conclusion
Discussions about cost do not always happen, even with diseases with potentially high medication costs like RA. Cost was more likely to be discussed by patients who perceived it as “very important,” suggesting the onus might be on patients to initiate these conversations. Without any significant predictors regarding what may make physicians more likely to think it was important to discuss medication costs, there is a need to reinforce recommendations that all physicians seek to discuss costs with all of their patients when suggesting medications.
Key Points • There is a need for patients and physicians to discuss costs in the treatment decision-making process. Our findings suggest this does not always happen. • Among patients, medication cost was more likely to be discussed by those who perceived it as “very important” and higher perceived importance of discussing out-of-pocket costs was associated with a more positive attitude to shared decision-making. • Our results did not reveal any significant predictors regarding what may make physicians more likely to think it was important to discuss medication costs, suggesting that there is a need to reinforce recommendations that all physicians seek to discuss medication costs with all of their patients when suggesting medications. |
This is a preview of subscription content, access via your institution.



References
Singh JA, Saag KG, Bridges SL, Akl EA, Bannuru RR, Sullivan MC et al (2016) 2015 American College of Rheumatology Guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol Hoboken 68:1–26
Finckh A, Deane KD (2014) Prevention of rheumatic diseases: strategies, caveats and future directions. Rheum Dis Clin N Am 40:771–785
Canadian Institute for Health Information (2016) Prescribed drug spending in Canada, 2016: a focus on public drug programs. CIHI, Ottawa
Eisenberg Center at Oregon Health & Science University. Choosing medications for rheumatoid arthritis: clinician’s guide. Comp Eff Rev Summ Guid Clin [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2007 [cited 2018 Jun 24]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK43422/
Mukherjee K, Kamal KM (2017) Sociodemographic determinants of out-of-pocket expenditures for patients using prescription drugs for rheumatoid arthritis. Am Health Drug Benefits 10:7–15
Law MR, Cheng L, Dhalla IA, Heard D, Morgan SG (2012) The effect of cost on adherence to prescription medications in Canada. CMAJ Can Med Assoc J J Assoc Medicale Can 184:297–302
Hennessy D, Sanmartin C, Ronksley P, Weaver R, Campbell D, Manns B et al (2016) Out-of-pocket spending on drugs and pharmaceutical products and cost-related prescription non-adherence among Canadians with chronic disease. Health Rep 27:3–8
Wolfe F, Michaud K (2009) Out-of-pocket expenses and their burden in patients with rheumatoid arthritis. Arthritis Rheum 61:1563–1570
Law MR, Cheng L, Kolhatkar A, Goldsmith LJ, Morgan SG, Holbrook AM, Dhalla IA (2018) The consequences of patient charges for prescription drugs in Canada: a cross-sectional survey. CMAJ Open 6:E63–E70
Sabaté E, World Health Organization, editors (eds) (2003) Adherence to long-term therapies: evidence for action. World Health Organization, Geneva
Vera MAD, Mailman J, Galo JS (2014) Economics of non-adherence to biologic therapies in rheumatoid arthritis. Curr Rheumatol Rep 16:460
Patel MR, Wheeler JRC (2014) Physician–patient communication on cost and affordability in asthma care. Who wants to talk about it and who is actually doing it. Ann Am Thorac Soc 11:1538–1544
Alexander GC, Casalino LP, Meltzer DO (2003) Patient-physician communication about out-of-pocket costs. JAMA. 290:953–958
Harrison M, Bansback N, Aguiar M, Koehn C, Shojania K, Finckh A et al (2020) Preferences for treatment to prevent rheumatoid arthritis in Canada and the influence of shared-decision-making. Clin Rheumatol. https://doi.org/10.1007/s10067-020-05072-w
Barr PJ, Thompson R, Walsh T, Grande SW, Ozanne EM, Elwyn G (2014) The psychometric properties of CollaboRATE: a fast and frugal patient-reported measure of the shared decision-making process. J Med Internet Res 16:e2
SAS 9.4. North Carolina, USA: SAS (2012)
Hall J, Julia Kaal K, Lee J, Duncan R, Tsao N, Harrison M (2018) Patient satisfaction and costs of multidisciplinary models of care in rheumatology: a review of the recent literature. Curr Rheumatol Rep [Internet]. [cited 2019 Jul 17];20. Available from: http://link.springer.com/10.1007/s11926-018-0727-3
Blumenthal-Barby JS, Robinson E, Cantor SB, Naik AD, Russell HV, Volk RJ (2015) The neglected topic: presentation of cost information in patient decision aids. Med Decis Mak 35:412–418
Canadian Institute for Health Information (2016) National Health Expenditure Trends, 1975 to 2016. CIHI, Ottawa
Goldsmith LJ, Kolhatkar A, Popowich D, Holbrook AM, Morgan SG, Law MR (2017) Understanding the patient experience of cost-related non-adherence to prescription medications through typology development and application. Soc Sci Med 194:51–59
Bansback N, Phibbs CS, Sun H, O’Dell JR, Brophy M, Keystone EC et al (2017) Triple therapy versus biologic therapy for active rheumatoid arthritis: a cost-effectiveness analysis. Ann Intern Med 167:8–16
Barber CEH, Jewett L, Badley EM, Lacaille D, Cividino A, Ahluwalia V, Averns H, Baillie C, Ellsworth J, Pope J, Levy D, Charnock C, McGowan C, Thorne JC, Barnabe C, Zummer M, Lundon K, McDougall RS, Thomson JG, Yacyshyn EA, Mosher D, Brophy J, Ruban TN, Marshall DA (2017) Stand up and be counted: measuring and mapping the rheumatology workforce in Canada. J Rheumatol 44:248–257
Campbell DJT, Manns BJ, Soril LJJ, Clement F (2017) Comparison of Canadian public medication insurance plans and the impact on out-of-pocket costs. CMAJ Open 5:E808–E813
Funding
This research was funded by a 2015 Canadian Initiative for Outcomes in Rheumatology cAre (CIORA) grant. Mark Harrison is supported by a Young Investigator Salary Award 2016 from The Arthritis Society (YIS-16-104) and a Michael Smith Foundation for Health Research Scholar Award 2017 (#16813).
Mark Harrison held the UBC Professorship in Sustainable Health Care, which between 2014 and 2017 was funded by Amgen Canada, AstraZeneca Canada, Eli Lilly Canada, GlaxoSmithKline, Merck Canada, Novartis Pharmaceuticals Canada, Pfizer Canada, Boehringer Ingelheim (Canada), Hoffman-La Roche, LifeScan Canada, and Lundbeck Canada.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
MHa and MHu report grants from CIORA during the conduct of the study. All other authors have nothing to disclose.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Kaal, K.J., Bansback, N., Hudson, M. et al. Patient-provider communication about medication cost in rheumatoid arthritis. Clin Rheumatol 40, 93–100 (2021). https://doi.org/10.1007/s10067-020-05188-z
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-020-05188-z
Keywords
- Communication
- Medication cost
- Patient-centered
- Rheumatoid arthritis